CMS-5528-IFC - Most Favored Nations Rx pricing is a lot to read. I suggest some key components of the program at the front of the interim final rule, then skip to section VI, Regulatory Impact Analysis, where the interim final rule covers what happens ...

I agree this is a great topic. The transparency on pricing and even how that is communicated (by payers, media, and pharmacies) prior to go-live will likely have a large impact on preventing/creating barriers to the uptake. We had completed some consumer ...

It appears the Moderna vaccine, which is capable of being refrigerated for 30 days and I believe 6 months in a freezer, would be the more appropriate choice for most practices. There will likely be a huge demand and limited supply for some time, so ...

Really liking the JMCP new cover. Uncluttered, crisp, clean. Nice! ------------------------------ Patrick Gleason Asst Vice President, Health Outcomes Prime Therapeutics LLC ------------------------------

Given new data and remdesivir's expanded label to include less severely ill patients, ICER now suggests a health-benefit price benchmark of $2,470 for hospitalized patients with moderate-to-severe disease, and $70 for patients hospitalized with milder ...